Study points to topical clove oil for canine sarcoptic mange

A new randomized controlled trial suggests topical clove oil could become a credible plant-based treatment candidate for canine sarcoptic mange. In the study, published August 10, 2026, in Frontiers in Veterinary Science, investigators reported that a high-dose clove oil regimen cleared mites in all 20 dogs assigned to that arm by day 14, outperforming topical amitraz on cure endpoints and producing marked improvement in mite-associated dermatitis. (frontiersin.org)

The work builds on earlier in vitro evidence that clove oil, and especially its major constituent eugenol, has acaricidal activity against Sarcoptes scabiei. The authors said their group had previously characterized a proposed mechanism involving inhibition of mitochondrial complex I in mites. That mechanistic background matters because sarcoptic mange still presents practical challenges in the clinic: the disease is highly contagious, intensely pruritic, and can resemble allergic or infectious dermatoses, while mites may be difficult to find even with properly collected scrapings. (frontiersin.org)

In the clinical trial, 100 naturally infested dogs in Lanzhou, China, were randomized into five groups of 20: low-, medium-, and high-dose clove oil, amitraz, and untreated control. Treatments were applied topically on days 0, 2, 4, and 6, with final assessment on day 14. The study found the comprehensive infection index fell 93.25% in the high-dose clove oil group, 85.12% in the medium-dose group, 84.18% in the amitraz group, and 65.23% in the low-dose group. By day 14, 20 of 20 dogs in the high-dose group were mite-free, versus 12 of 20 in the medium-dose group, 2 of 20 in the low-dose group, 10 of 20 in the amitraz group, and 0 of 20 controls. Complete resolution of mite density-related dermatitis was also seen in all 20 dogs in the high-dose group. (frontiersin.org)

On safety, the paper reported that food intake, water consumption, behavior, and local skin tolerance remained clinically acceptable across treated groups, with no treatment-related skin irritation or other clinically relevant adverse abnormalities observed during the 14-day canine study. The authors also included rat safety pharmacology work and reported no apparent adverse cardiovascular, respiratory, or central nervous system effects after dermal exposure. Still, they explicitly cautioned against overreading those findings as definitive evidence of safety, given the short study duration and field-study variability. (frontiersin.org)

Independent expert reaction specific to this paper was limited in public sources at the time of writing, but the broader dermatology context is clear. A Canadian Veterinary Journal review by board-certified dermatologist Vincent Defalque described isoxazolines as having “impressive results” for canine sarcoptic mange and summarized multiple studies showing high mite-clearance rates with afoxolaner, fluralaner, lotilaner, and sarolaner. In that context, clove oil is not displacing current first-line therapies yet, but it does enter the conversation as a potentially lower-cost topical alternative worth further evaluation. (canadianveterinarians.net)

Why it matters: For veterinary professionals, the study is most relevant as a proof-of-concept with practical implications. In shelters, breeding operations, and cost-sensitive cases, a plant-derived topical with meaningful acaricidal activity could be attractive if it proves reproducible, scalable, and safe. The paper also raises an interesting clinical point: lesion improvement appeared to track closely with mite reduction, and the authors argue clove oil’s anti-inflammatory and antimicrobial properties may have contributed to faster skin recovery. But the tradeoffs are real. Unlike oral or spot-on isoxazolines, the clove oil protocol required repeated manual application and glove use, which could limit uptake in busy practice settings. (frontiersin.org)

There are also important limits. This was a single-country study with 100 dogs, short follow-up, and comparison to amitraz rather than to modern isoxazoline protocols that many clinicians now regard as standard of care. The paper itself notes that isoxazoline-based therapies are the contemporary standard, and outside reviews support that framing. Until larger head-to-head trials are available, clove oil should be viewed as investigational rather than practice-changing. (frontiersin.org)

What to watch: The next step is whether researchers pursue longer-term studies with relapse monitoring, standardized formulations, and direct comparisons against oral and topical isoxazolines, as well as whether any commercial or regulatory development follows from this early efficacy signal. (frontiersin.org)